Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Terheyden

Showing results (51-60 of 130) with videos related to

Pageof 13
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 26, 2014
Stereotactic radiosurgery for newly diagnosed brain metastases: comparison of three dose levelsDirk Rades, Dagmar Hornung, Oliver Blanck, et al.
Frontiers in Immunology|March 12, 2021
Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology CentersChristian D Sadik, Ewan A Langan, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityRalf Gutzmer, Anika Koop, Friedegund Meier, et al.
JAMA Oncology|March 23, 2018
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical TrialSandra P D'Angelo, Jeffery Russell, Céleste Lebbé, et al.
Plos One|August 17, 2019
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockadeJonas Bochem, Henning Zelba, Teresa Amaral, et al.
European Journal of Cancer Care|August 21, 2018
Fear of cancer progression in patients with stage IA malignant melanomaTobias Wagner, Matthias Augustin, Christine Blome, et al.
Cancer Immunology, Immunotherapy : CII|March 1, 2018
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disordersKatharina C Kähler, Thomas K Eigentler, Anja Gesierich, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2017
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanomaKatrin Schaper-Gerhardt, Steven Okoye, Rudolf Herbst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIvelina Spassova, Selma Ugurel, Patrick Terheyden, et al.
Melanoma Research|November 14, 2023
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNISKatharina C Kähler, Dirk Debus, Gaston Schley, et al.
Pageof 13

Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 26, 2014
Stereotactic radiosurgery for newly diagnosed brain metastases: comparison of three dose levelsDirk Rades, Dagmar Hornung, Oliver Blanck, et al.
Frontiers in Immunology|March 12, 2021
Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology CentersChristian D Sadik, Ewan A Langan, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityRalf Gutzmer, Anika Koop, Friedegund Meier, et al.
JAMA Oncology|March 23, 2018
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical TrialSandra P D'Angelo, Jeffery Russell, Céleste Lebbé, et al.
Plos One|August 17, 2019
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockadeJonas Bochem, Henning Zelba, Teresa Amaral, et al.
European Journal of Cancer Care|August 21, 2018
Fear of cancer progression in patients with stage IA malignant melanomaTobias Wagner, Matthias Augustin, Christine Blome, et al.
Cancer Immunology, Immunotherapy : CII|March 1, 2018
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disordersKatharina C Kähler, Thomas K Eigentler, Anja Gesierich, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2017
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanomaKatrin Schaper-Gerhardt, Steven Okoye, Rudolf Herbst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIvelina Spassova, Selma Ugurel, Patrick Terheyden, et al.
Melanoma Research|November 14, 2023
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNISKatharina C Kähler, Dirk Debus, Gaston Schley, et al.
Pageof 13